All stock reports

PPLPHARMA evidence report

Evidence date: 2026-10-01. Research observations only.

What can I do with this stock?

Evaluated 2026-10-02T01:37:53.224812+00:00. Closed-session evidence: 2026-10-01. This is a timestamped assessment, not a live trading feed.

Strategy evidence, instrument feasibility and portfolio suitability are separate. Portfolio suitability has not been assessed.

Today: intraday

Evidence unavailable

No current intraday signal and observed quote supplied; daily bars cannot establish a live setup.

  • No current intraday signal and observed quote supplied; daily bars cannot establish a live setup.

Next week: five trading sessions

No qualifying opportunity

No candidate with a primary five-session horizon in the coherent source run.

  • No candidate with a primary five-session horizon in the coherent source run.

Long term: one to three years

Research only

A financial screen alone does not establish an investment recommendation.

  • Financial data quality flags require resolution.
  • A current, source-backed thesis and valuation review is required.

Investment evidence

Statement coverage
FULL_STATEMENTS
Financial source retrieved
2026-09-28T14:01:32.020713+00:00

Metrics

latest_annual_period
2026-03-31
revenue
88690800000.0
net_income
-3259400000.0
operating_cash_flow
13995600000.0
free_cash_flow
5095400000.0
total_assets
179650400000.0
total_liabilities
98024200000.0
total_equity
81626200000.0
cash
12236400000.0
total_debt
56745900000.0
revenue_growth
-0.021180885112018544
earnings_growth
-4.576648743553166
net_margin
-0.036750147704158714
roe
-0.03993080653025622
debt_to_equity
0.6951922299457772
cash_conversion
-4.293919126219549
free_cash_flow_margin
0.057451280177876395
trailing_pe
Not supplied
forward_pe
0.0
peg_ratio
Not supplied
price_to_book
3.1808
dividend_yield
Not supplied

Other positional research

No qualifying opportunity

No candidate at another positional horizon in the coherent source run.

  • No candidate at another positional horizon in the coherent source run.
Decision provenance and limitations
Decision ID
decision-4a85a3e057b3724dce152e4817afca0479d2b2a6fe6bc5724ebe55bb1aa25b82
Policy
stock-decisions-v1
Evidence bundle hash
c64ba761af7ae5e9ba4d931ac815fb1be756cff289d81b22b909c43519f3c6a1
  • market-brief: a7de4d64fedac164d48cdfb9b4081a4666d7f797f7d9c58da304b329b3a61d3c
  • validation-registry: b1069587129bfc64a703cdf8322d0294692585b7d67f5472593e4164bbb0c3bc
  • financial-statements: 3d5c0cabd3b78daef0d2f363b73e10692fbd2a902ce7fe9269486c3f9960fcc1
  • daily-price: aa5952e238a6b7709b27600e1c1c28235ed98390b7326da41d8051b174c8cfdf
  • Conditional research decisions are not orders or personalized position sizes.
  • Scenario payoffs are assumptions, not probabilities or expected returns.
  • A stop price does not guarantee a maximum loss through a gap or illiquidity.

Download the decision evidence as JSON

Evidence briefing

The local language model selected and grouped the following supplied facts.

Overview

Price source verification: REPAIRED. The trailing 60-session price return was 17.76%. The cached financial metric latest annual period is 2026-03-31. Average cached traded value over twenty sessions was INR 911,338,989.

Risks

The trailing 5-session price return was -4.88%. The trailing 20-session price return was -7.40%. The closing price was -12.64% below its highest close in the available trailing year. The cached financial metric net margin is -0.036750147704158714. The cached financial metric roe is -0.03993080653025622. Financial data check: weak_cash_conversion: operating cash flow/net income below 0.5.

Follow Up

The cached financial metric revenue growth is -0.021180885112018544. The cached financial metric cash conversion is -4.293919126219549. The cached financial metric free cash flow margin is 0.057451280177876395. Historical observations do not establish future returns. No verified current news or catalyst evidence is supplied.

Cached observations and evidence limits